Compartilhar
Informação da revista
Vol. 46. Núm. S4.
HEMO 2024
Páginas S565-S566 (outubro 2024)
Vol. 46. Núm. S4.
HEMO 2024
Páginas S565-S566 (outubro 2024)
Acesso de texto completo
SURGICAL EXPERIENCE IN PEOPLE WITH HEMOPHILIA A OR B WITH AND WITHOUT INHIBITORS RECEIVING FITUSIRAN
Visitas
349
Alok-Srivastavaa,b, Pencho-Georgievc, Toshko-Lissitchkovd, M V-Ragnie, Juliana-Aragaof, L A-Menapaceg, Yuqian-Shenh, Marja-Puuruneng, Marek-Demissieg, S W-Pipei
a Department of Haematology, Christian Medical College (CMC), Vellore India
b Centre for Stem Cell Research (CSCR), inStem, Vellore, India
c University Multiprofile Hospital for Active Treatment “Sveti Georgi”and Medical University Plovdiv, Bulgaria
d Clinic Specialized Hospital for Active Treatment of Haematological Diseases, Sofia, Bulgaria
e University of Pittsburgh and Hemophilia Center of Western Pennsylvania (HCWP), Pittsburgh, PA, United States
f Sanofi Medley Farmaceutica Ltda, Suzano, São Paulo, SP, Brazil
g Sanofi, Cambridge, MA, United States
h Sanofi, Bridgewater, NJ, United States
i Departments of Pediatrics and Pathology, University of Michigan (UM), Ann Arbor, MI, United States
Ver más
Este item recebeu
Informação do artigo
Suplemento especial
Este artigo faz parte de:
Vol. 46. Núm S4

HEMO 2024

Mais dados
Background

Fitusiran, a subcutaneous, investigational siRNA therapeutic lowers antithrombin to rebalance hemostasis and enhance thrombin generation in People with Hemophilia (PwH) A or B, regardless of inhibitor status. For the management of perioperative hemostasis, Bleed Management Guidelines (BMG) with reduced dose and/or frequency of Clotting Factor Concentrates (CFC), or Bypassing Agents (BPA) were implemented.

Aims

To describe hemostatic outcomes of major surgeries conducted while on fitusiran prophylaxis in PwHA/B aged ≥12-years, regardless of inhibitor status.

Methods

All major surgeries in the fitusiran clinical development program until June 2023 were evaluated, including participants on the 80 mg QM and revised antithrombin-based dose regimen. Informed consent and ethics committee approval were obtained for all studies. Procedures conducted during fitusiran prophylaxis and AT activity < 60% were included. Major surgeries included: opening into a major body cavity, operation on a joint, removal of an organ, operative alteration of normal anatomy, crossing of a mesenchymal barrier, dental extraction of molar teeth or ≥3 nonmolar teeth, or tooth implantation. Investigators/surgeon assessed peri-operative hemostatic control based on the ISTH 4-point response scale (excellent/good/moderate/poor).

Results and discussion

Sixty major surgeries (24 in inhibitor patients) were performed. In 47 (78.3%) major surgeries, BMG were followed, and reduced doses were used as perioperative prophylaxis. Four major surgeries were conducted without additional CFC/BPA. Hemostatic control on the day of the surgery was rated excellent/good in 30/31 (97%) cases following BMG and 9/10 (90%) cases not following BMG. ATIII concentrate was used to reverse the pharmacodynamic effect of fitusiran in 7 surgeries with an excellent/good hemostatic outcome. No major treatmentrelated safety concerns were identified perioperatively. Postoperative thrombosis occurred only when dosing exceeded BMG recommendations in 2 participants.

Conclusions

Major surgeries can be safely and effectively conducted during fitusiran prophylaxis when BMG are followed, irrespective of inhibitor status. Reversal of lowered AT is not necessary.

O texto completo está disponível em PDF
Baixar PDF
Idiomas
Hematology, Transfusion and Cell Therapy
Opções de artigo
Ferramentas